Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Fromm

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
MMW Fortschritte Der Medizin|February 5, 2002
[Unexpected high plasma level of drugs. Blocked transporter can be the cause]M F Fromm
International Journal of Clinical Pharmacology and Therapeutics|March 8, 2000
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugsM F Fromm
European Journal of Clinical Investigation|December 4, 2003
Importance of P-glycoprotein for drug disposition in humansM F Fromm
Clinical Pharmacology and Therapeutics|October 23, 2012
Prediction of transporter-mediated drug-drug interactions using endogenous compoundsM F Fromm
Clinical Pharmacology and Therapeutics|April 8, 2011
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactionsO Zolk, M F Fromm
Fortschritte Der Medizin|August 30, 1995
[Mirror, mirror on the wall--stereoselectivity of drug effects]M F Fromm, H K Kroemer
British Journal of Pharmacology|August 11, 2011
Interaction of innovative small molecule drugs used for cancer therapy with drug transportersK Mandery, H Glaeser, M F Fromm
Zeitschrift Fur Gastroenterologie|January 13, 2011
[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]T Rabenstein, M F Fromm, O Zolk
Scientific Reports|April 29, 2018
Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO)A Gessner, J König, M F Fromm
Therapeutic Drug Monitoring|August 1, 1996
Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and inductionH K Kroemer, M F Fromm, M Eichelbaum
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
MMW Fortschritte Der Medizin|February 5, 2002
[Unexpected high plasma level of drugs. Blocked transporter can be the cause]M F Fromm
International Journal of Clinical Pharmacology and Therapeutics|March 8, 2000
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugsM F Fromm
European Journal of Clinical Investigation|December 4, 2003
Importance of P-glycoprotein for drug disposition in humansM F Fromm
Clinical Pharmacology and Therapeutics|October 23, 2012
Prediction of transporter-mediated drug-drug interactions using endogenous compoundsM F Fromm
Clinical Pharmacology and Therapeutics|April 8, 2011
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactionsO Zolk, M F Fromm
Fortschritte Der Medizin|August 30, 1995
[Mirror, mirror on the wall--stereoselectivity of drug effects]M F Fromm, H K Kroemer
British Journal of Pharmacology|August 11, 2011
Interaction of innovative small molecule drugs used for cancer therapy with drug transportersK Mandery, H Glaeser, M F Fromm
Zeitschrift Fur Gastroenterologie|January 13, 2011
[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]T Rabenstein, M F Fromm, O Zolk
Scientific Reports|April 29, 2018
Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO)A Gessner, J König, M F Fromm
Therapeutic Drug Monitoring|August 1, 1996
Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and inductionH K Kroemer, M F Fromm, M Eichelbaum
Pageof 6